Related Experiment Videos
[Ebstein's anomaly: valvular replacement in pediatric patients]
E Saro-Servando1, J S Vobecky, C Chartrand
1Service de Chirurgie Cardio-Vasculaire, Hôpital Sainte-Justine, Montréal, Québec, Canada.
Annales De Chirurgie
|December 10, 1999
Summary
Tricuspid valve replacement (TVR) in children with Ebstein's anomaly shows promising results. This surgical treatment offers a low operative risk and improved functional status, suggesting it is a viable therapeutic option.
Area of Science:
- Cardiology
- Pediatric Surgery
- Congenital Heart Disease
Context:
- Ebstein's anomaly is a rare congenital heart defect affecting the tricuspid valve.
- Surgical treatment options, particularly tricuspid valve replacement (TVR), remain a subject of debate.
- This study retrospectively analyzes TVR outcomes in pediatric patients.
Purpose:
- To evaluate the efficacy and long-term results of tricuspid valve replacement (TVR) in children diagnosed with Ebstein's anomaly.
- To assess operative risk, functional improvement, and prosthesis durability in this patient cohort.
Summary:
- Nine pediatric patients with Ebstein's anomaly underwent tricuspid valve replacement (TVR) between 1977 and 1997.
- No operative mortality or complete heart block occurred; 20-year survival reached 88%.
- All surviving patients demonstrated improved functional class, with good bioprosthesis durability in the tricuspid position.
Impact:
- Tricuspid valve replacement (TVR) with bioprosthesis is a safe and effective treatment for pediatric Ebstein's anomaly.
- Improved functional status and favorable long-term survival rates support TVR as a therapeutic option.
- The study highlights the good durability of bioprosthetic valves in the tricuspid position for children.